» Articles » PMID: 37384719

An Amino Acid Substitution in HCV Core Antigen Limits Its Use As a Reliable Measure of HCV Infection Compared with HCV RNA

Abstract

Hepatitis C virus (HCV) is a viral pathogen that causes chronic hepatitis, which can lead to cirrhosis and hepatocellular carcinoma. Detection of HCV RNA is the standard method used to diagnose the disease and monitor antiviral treatment. A quantification assay for the HCV core antigen (HCVcAg) has been proposed as a simplified alternative to the HCV RNA test for predicting active HCV infection, with the aim of achieving the global goal of eliminating hepatitis. The objective of this study was to determine the correlation between HCV RNA and HCVcAg, as well as the impact of amino acid sequence heterogeneity on HCVcAg quantification. Our findings demonstrated a strong positive correlation between HCV RNA and HCVcAg across all HCV genotypes (1a, 1b, 3a, and 6), with correlation coefficients ranging from 0.88 to 0.96 (p < 0.001). However, in some cases, samples with genotypes 3a and 6 exhibited lower HCVcAg levels than expected based on the corresponding HCV RNA values. Upon the core amino acid sequence alignment, it was observed that samples exhibiting low core antigen levels had an amino acid substitution at position 49, where threonine was replaced by either alanine or valine. Core mutation at this position may correlate with one of the epitope regions recognized by anti-HCV monoclonal antibodies. The present findings suggest that the utilization of HCVcAg as a standalone marker for HCV RNA might not provide adequate sensitivity for the detection of HCV infection, especially in cases where there are variations in the amino acid sequence of the core region and a low viral load of HCV RNA.

Citing Articles

Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes.

Le D, Kanokudom S, Nguyen H, Yorsaeng R, Honsawek S, Vongpunsawad S Viruses. 2025; 16(12.

PMID: 39772172 PMC: 11680303. DOI: 10.3390/v16121863.


Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment.

Kanokudom S, Poovorawan K, Nilyanimit P, Suntronwong N, Aeemjinda R, Honsawek S PLoS One. 2024; 19(11):e0313771.

PMID: 39556526 PMC: 11573151. DOI: 10.1371/journal.pone.0313771.

References
1.
Nguyen L, Dunford L, Freitas I, Holder P, Nguyen L, OGorman J . Hepatitis C Virus Core Mutations Associated with False-Negative Serological Results for Genotype 3a Core Antigen. J Clin Microbiol. 2015; 53(8):2697-700. PMC: 4508445. DOI: 10.1128/JCM.01062-15. View

2.
Wasitthankasem R, Pimsingh N, Treesun K, Posuwan N, Vichaiwattana P, Auphimai C . Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward HCV Elimination. Am J Trop Med Hyg. 2020; 103(1):175-182. PMC: 7356443. DOI: 10.4269/ajtmh.19-0817. View

3.
Kumbhar N, Ramachandran K, Kumar G, Pasupuleti S, Sharma M, Gupta E . Utility of hepatitis C virus core antigen testing for diagnosis and treatment monitoring in HCV infection: A study from India. Indian J Med Microbiol. 2021; 39(4):462-466. DOI: 10.1016/j.ijmmb.2021.07.002. View

4.
Suzuki T, Ishii K, Aizaki H, Wakita T . Hepatitis C viral life cycle. Adv Drug Deliv Rev. 2007; 59(12):1200-12. DOI: 10.1016/j.addr.2007.04.014. View

5.
Thomas D . Global Elimination of Chronic Hepatitis. N Engl J Med. 2019; 380(21):2041-2050. DOI: 10.1056/NEJMra1810477. View